ten Bokkel Huinink W W, Lustig V, Dubbelman R, Hiemstra A, Rodenhuis S
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eur J Cancer. 1997 Aug;33 Suppl 7:S23-5. doi: 10.1016/s0959-8049(97)90006-x.
Docetaxel is one of the most active drugs used in the treatment of breast cancer. However, its major side-effect, myelosuppression, hampers full-dose combination chemotherapy. We have, therefore, developed an alternating schedule of docetaxel with epirubicin and cyclophosphamide, together with granulocyte colony-stimulating factor, to ameliorate neutropenia. We studied the feasibility of such a strategy, decreasing the treatment interval from 21 days to 14 days, thus further increasing the dose intensity. As expected, myelosuppression was common, complicated by neutropenic fever, which did not exceed preset criteria. Other side-effects were also as expected: alopecia, malaise, nausea and vomiting. After two alternating courses of chemotherapy, a partial response was documented in 15 of 17 patients. We conclude that this alternating schedule is very active against breast cancer and warrants further phase II studies.
多西他赛是治疗乳腺癌最有效的药物之一。然而，其主要副作用骨髓抑制阻碍了全剂量联合化疗。因此，我们制定了多西他赛与表柔比星和环磷酰胺交替给药方案，并联合使用粒细胞集落刺激因子以改善中性粒细胞减少。我们研究了这种策略的可行性，将治疗间隔从21天缩短至14天，从而进一步提高剂量强度。正如预期的那样，骨髓抑制很常见，并伴有未超过预设标准的中性粒细胞减少性发热。其他副作用也如预期：脱发、不适、恶心和呕吐。在两个交替化疗疗程后，17例患者中有15例记录有部分缓解。我们得出结论，这种交替给药方案对乳腺癌非常有效，值得进一步进行II期研究。
